Understanding Pancreatic Cancer: A Silent Killer
Pancreatic cancer, particularly pancreatic ductal adenocarcinoma (PDAC), remains one of the most lethal forms of the disease worldwide. Often diagnosed at advanced stages due to its lack of early symptoms, PDAC has a median survival time of just 12 months from diagnosis. The pancreas, a vital organ behind the stomach responsible for producing digestive enzymes and regulating blood sugar through insulin, becomes a battleground where malignant cells exploit the surrounding microenvironment to thrive and spread.
In Brazil, the burden is significant. According to estimates from the Instituto Nacional de Câncer (INCA), pancreatic cancer accounts for thousands of new cases annually, contributing to the rising cancer incidence projected at over 700,000 cases per year through 2025.
The Role of Perineural Invasion in PDAC Aggressiveness
One hallmark of PDAC's lethality is perineural invasion (PNI), where tumor cells infiltrate along nerve sheaths. Present in up to 100% of advanced cases, PNI facilitates early metastasis, recurrence, and severe pain, drastically worsening prognosis. This process involves complex interactions between cancer cells, nerves, and stromal cells, creating highways for dissemination that evade early detection.
Understanding PNI has been challenging, but recent research sheds light on key players in this microenvironmental conspiracy.
Spotlight on Periostin: The Matricellular Protein
Periostin (POSTN), also known as osteoblast-specific factor 2, is a matricellular protein secreted into the extracellular matrix (ECM). It plays roles in tissue remodeling, fibrosis, and cell adhesion. In cancer contexts, periostin promotes epithelial-to-mesenchymal transition (EMT), invasion, and resistance to therapy. Elevated POSTN levels correlate with poor outcomes in various malignancies, including PDAC.
In the pancreas, POSTN is overexpressed up to 42-fold in tumors compared to healthy tissue, highlighting its pathological significance.
Pancreatic Stellate Cells: The Tumor's Accomplices
Pancreatic stellate cells (PSCs) are quiescent fibroblasts that activate in response to injury or cancer signals. Activated PSCs (aPSCs) produce ECM components like collagen and fibronectin, leading to desmoplasia—a dense, fibrotic stroma around the tumor. This stroma comprises up to 90% of PDAC mass, acting as a physical barrier to drugs and a facilitator of invasion.
Recent findings reveal that POSTN-producing PSCs are central to PNI.
The Groundbreaking Brazilian Study
A pioneering study from researchers at the University of São Paulo (USP) has elucidated how POSTN-positive PSCs drive PNI in PDAC. Published in Molecular and Cellular Endocrinology, the paper "Periostin-positive stellate cells associated with perineural invasion in pancreatic adenocarcinoma" details analyses of patient tumor samples.
Led by Carlos Alberto de Carvalho Fraga from USP's Faculdade de Medicina (FMUSP), the team collaborated with experts from Hospital das Clínicas (HC-FMUSP). Funded by FAPESP, this work underscores Brazil's growing contributions to oncology research through its top universities. For those pursuing careers in cancer research, opportunities abound at institutions like USP via research jobs and university jobs in Brazil.
Methods Employed in the Research
The study integrated immunohistochemistry (IHC), spatial transcriptomics, and in vitro assays on human PDAC samples. Researchers identified PSCs expressing high POSTN, collagens (I, III, VI), and metalloproteinases (MMPs) enriched around nerves in PNI-positive tumors.
- IHC staining for POSTN and PSC markers (e.g., α-SMA) on tissue microarrays from 50+ patients.
- RNA sequencing to profile gene expression in PNI regions.
- Co-culture models showing PSC-derived POSTN enhances cancer cell migration toward nerves.
These rigorous methods confirmed POSTN's mechanistic role.
Key Findings: How Periostin Fuels Invasion
The research demonstrated that POSTN from PSCs remodels the ECM, increasing stiffness and depositing aligned collagen fibers that guide cancer cells along nerves. This creates a pro-inflammatory niche with elevated cytokines, further activating PSCs in a vicious cycle.
PNI-positive tumors showed 3-fold higher POSTN+ PSC density. Blocking POSTN reduced invasion in preclinical models, suggesting therapeutic promise.
Read the full FAPESP reportMechanisms Step-by-Step
- Cancer cells signal PSCs via TGF-β and other factors.
- Activated PSCs secrete POSTN, collagens, MMPs.
- POSTN binds integrins on cancer cells, promoting EMT and motility.
- Remodeled ECM forms tracks along nerves; inflammation recruits more PSCs.
- Tumor invades nerves, metastasizes to distant sites.
This step-by-step process explains PDAC's neurotropism.
Therapeutic Implications and Future Targets
Targeting POSTN or PSC activation could disrupt PNI. Preclinical data show POSTN inhibitors reduce fibrosis and invasion. Combined with chemotherapy like gemcitabine, this might enhance efficacy. Clinical trials are warranted.
Stakeholders, including oncologists and patients, welcome these insights. As Dr. Fraga noted, "This opens avenues for stromal-targeted therapies." For Brazilian researchers advancing such work, explore research assistant jobs or academic CV tips.
Access the study abstract on PubMedPancreatic Cancer Landscape in Brazil
INCA projects steady rises in pancreatic cancer cases, with ~11,000 new diagnoses yearly amid lifestyle shifts like obesity and smoking. Survival lags due to late diagnosis; only 20% are operable. Regional disparities persist, with higher mortality in urban South/Southeast.
- Risk factors: Smoking (25% cases), obesity, diabetes, chronic pancreatitis.
- Prevention: Healthy weight, no tobacco, balanced diet.
Brazilian universities like USP lead efforts, fostering innovation.
USP's Contributions to Oncology Research
USP, Brazil's premier university, hosts cutting-edge labs at FMUSP and HC. This study exemplifies interdisciplinary work in pathology, molecular biology, and bioinformatics. Such research attracts global talent; check Brazil higher ed jobs or professor jobs for openings.
Funding from FAPESP bolsters these initiatives, positioning Brazil as a Latin American hub for cancer studies.
Global Context and Comparative Insights
Globally, PDAC incidence rises, projected to be 3rd deadliest by 2030. Similar POSTN roles appear in breast, prostate cancers. Brazilian findings align with international PSC research, suggesting universal therapeutic strategies.
INCA Cancer EstimatesPhoto by Alessandro Di Credico on Unsplash
Future Outlook: From Bench to Bedside
Prospects include POSTN-blocking antibodies, PSC-depleting agents, or ECM softeners. Biomarker potential for PNI prediction via blood POSTN levels. Ongoing trials and USP follow-ups promise progress. Patients gain hope; researchers, new frontiers.
Engage with the field: Rate professors at Rate My Professor, seek higher ed jobs, or read career advice. Share insights in comments below.